The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus: Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM

Annals of Internal Medicine

Volumn 124, Issue 1 II, 1996, Pages 131-135

  Colwell, John A ^a,b  

^a Dept Vet Aff Coop Studs Prog ^*  (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIPIZIDE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; AGED; BLOOD GLUCOSE MONITORING; BODY MASS; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG EFFICACY; FOLLOW UP; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0030034273     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-124-1_part_2-199601011-00010     Document Type: Conference Paper

References (34)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 1993,16.434-44
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993,329 977-86
3. University Group Diabetes Program VII Evaluation of insulin therapy - final report Diabetes 1982;31 14
4. University Group Diabetes Program I Design, methods and baseline results. Diabetes 1970,19(Suppl 2):747-83
5. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes II Mortality results Diabetes, 1970;19(Suppl 2):789-830.
6. 1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes A multicenter study Diabetes 1985;34 793-8
7. U K Prospective Diabetes Study (UKPDS) VIII Study design, progress and performance Diabetologia 1991;34:877-90.
8. Klein R, Klein BE, Moss SE, Shrago ES, Spennetta TL. Glycosylated hemoglobin in a population-based study of diabetes Am J Epidemiol 1987; 126.415-28.
9. Abraira C, Emanuele N, Colwell J, Henderson W, Comstock J, Levin S, et al. Giycemic control and complications in type II diabetes. Design of a feasibility trial Diabetes Care 1992,15.1560-71.
10. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, et al. VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VACSDM). Results of the feasibility trial Diabetes Care. 1995,[In press]
11. Holman RR, Turner RC. The basal plasma glucose: a simple relevant index of maturity-onset diabetes Clin Endocrinol (Oxf) 1981;14:279-86
12. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus Diabetes 1985,34.222-34
13. DeFronzo RA. Lilly lecture 1987. The triumvirate, beta-cell, muscle, liver. A collusion responsible for NIDDM Diabetes 1988,37.667-87
14. Vague P, Moulin JP. The defective glucose sensitivity of the B cell in non insulin dependent diabetes Improvement after twenty hours of normoglycaemia. Metabolism 1982,31:139-42
15. Riddle MC. New tactics for type 2 diabetes regimens based on intermediate-acting insulin taken at bedtime Lancet. 1985,1.192-5
16. Trischitta V, Italia S, Borzi V, Tribulato A, Mazzarino S, Squatrito S, et al. Low-dose bedtime NPH insulin in treatment of secondary failure to glyburide Diabetes Care 1989,12 582-5
17. Taskinen MR, Sane T, Helve E, Karonen SL, Nikkila EA, Yki-Jarvinen H, et al. Bedtime insulin for suppression of overnight free-fatty acid, blood glucose, and glucose production in NIDDM. Diabetes 1989;38:580-8
18. McMahon M, Marsh HM, Rizza RA. Effects of basal insulin supplementation on disposition of mixed meal in obese patients with NIDDM Diabetes 1989,38 291-303.
19. Riddle MC. Evening insulin strategy Diabetes Care. 1990,13.676-86
20. Siegler DE, Olson M, Skyler JS. Morning versus bedtime NPH insulin in type II (non-insulin dependent) diabetes mellitus. Diabetologia 1987, 30.581A.
21. Groop LC, Widen E, Ekstrand A, Saloranta C, Franssila-Kallunki A, Schalin-Jantti C, et al. Morning or bedtime NPH insulin combined with sulfonylurea in treatment of NIDDM. Diabetes Care 1992,15:831-4.
22. Groop L, Groop PH, Stenman S, Saloranta C, Totterman KJ, Fyhrquist F, et al. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment Diabetes Care 1987;10 71-8.
23. Firth RG, Bell PM, Rizza RA. Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1986,314:1280-6
24. Riddle MC, Hart JS, Bouma DJ, Phillipson BE, Youker G. Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects Diabetes Care 1989,12 623-9
25. Groop LC, Groop PH, Stenman S. Combined insulin-sulfonylurea therapy in treatment of NIDDM Diabetes Care 1990,13(Suppl 3):47-52.
26. Soneru IL, Agrawal L, Murphy JC, Lawrence AM, Abraira C. Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure. Diabetes Care 1993,16:896-901
27. Stolar MW. Atherosclerosis in diabetes: the role of hyperinsulinemia Metabolism. 1988,37(2 Suppl 1):1-9
28. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and nondiabetic subjects. Diabetologia 1993;36:1175-84.
29. Krolewski AS, Warram JH, Valsania P, Martin BC, Laffel LM, Christlieb AR. Evolving natural history of coronary artery disease in diabetes mellitus Am J Med 1991,90(Suppl 2A) 56S-61S
30. Kuusisto J, Mykkamen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects Diabetes. 1994; 43 960-7
31. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus Early Treatment Diabetic Retinopathy Study report 14 JAMA 1992,268 1292-300
32. Janka HU. Five-year incidence of major macrovascular complications in diabetes mellitus. Horm Metab Res. 1985;15(Suppl) 15-9.
33. Janka HU, Balletshofer B, Becker A, Gick MR, et al. Das metabolische Syndrom als potenter kardiovaskularer Risikofaktor fur vorzeitigen Tod bei Typ-II-Diabetikern. Die Schwabinger Studie II Untersuchung nach neun Jahren Diabet Stoffwechs 1997,1.2-7
34. Colwell JA. DCCT findings. Applicability and implications for NIDDM Diabetes Reviews 1994;2 277-91.